Opinion|Videos|January 31, 2025
Assessing Treatment Options for ALK+ NSCLC
This video segment provides an in-depth discussion on the first-line use of lorlatinib for ALK-positive metastatic NSCLC, including clinical evidence from the phase 3 CROWN trial, the broader therapeutic landscape and alternative strategies, real-world insights on lorlatinib's performance, and key considerations for selecting among ALK inhibitors based on patient-specific factors.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you summarize the clinical evidence supporting lorlatinib use in the first-line treatment of ALK+ metastatic NSCLC?
- Could you highlight the primary efficacy outcomes from the phase 3 CROWN trial?
- How would you describe the current therapeutic landscape metastatic ALK+ NSCLC?
- What alternative treatment strategies could have been considered for this patient?
- Based on your clinical experience, how has lorlatinib performed in real-world practice?
- What advantages and challenges have you encountered when incorporating lorlatinib into your treatment protocols?
- How do you approach the selection process among the various available ALK inhibitors?
- What key factors influence your decision?
- In which specific patient subgroups would you lean towards using alectinib, lorlatinib, or brigatinib (the NCCN preferred treatments)?
Advertisement
Related to this article
Clinicians must think a lot about how to make testing and novel treatment advances available for patients globally, according to Chul Kim, MD, MPH.
Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small cell lung cancer.
Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 PAPILLON trial.
Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full approval.
David R. Gandara, MD, discusses how EMPOWER-Lung 1’s findings in KRAS G12C-mutated disease should inform the design of combination trials.
David R. Gandara, MD, explains what makes KRAS G12C biologically distinct from other KRAS subtypes in NSCLC immunotherapy response.
Xiuning Le, MD, PhD, weighs sevabertinib against zongertinib and trastuzumab deruxtecan in HER2-mutant non–small cell lung cancer.
Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
2
BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma
3
Integrating Talazoparib Plus Enzalutamide Into HRR-Mutated mHSPC Care
4
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
5